About idelalisib
PI3K-delta inhibitor
Used for
- Certain relapsed chronic lymphocytic leukemia, with rituximab
- Relapsed follicular lymphoma after at least two prior treatments
- Relapsed small lymphocytic lymphoma after at least two prior treatments
Usual adult dose
150 mg by mouth twice daily for approved uses; treatment may be adjusted or stopped for toxicity.
Common side effects
- Diarrhea or colitis
- Liver inflammation and abnormal liver tests
- Lung inflammation
- Infections, including serious infections
Important warnings
- Can cause severe or fatal diarrhea, liver injury, lung inflammation, or infection.
- Blood tests and infection monitoring are required during treatment.
- Avoid live vaccines; treatment may need interruption for serious side effects.
- Use only for specific cancers under specialist supervision.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least one month afterward.
Breastfeeding
Do not breastfeed during treatment and for at least one month after the final dose.
Interactions
- Strong CYP3A inhibitors can increase idelalisib exposure.
- Strong CYP3A inducers can reduce idelalisib exposure.
- Idelalisib can increase levels of CYP3A-metabolized medicines, including some sedatives and statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.